drugset / Trial / NCT00002210

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

NCT00002210

Phase 2 Completed 24 enrolled Pharmacia and Upjohn
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.

Timeline

Start
Primary completion
Completion

Publications

  • Background Willoughby R, Watson D, Welliver R. Early use of RESCRIPTOR (delavirdine) in children with HIV. 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29 (abstract no 1995)

Drugs

EvaluationDrugModalityDoseRoute
Subject Delavirdine Small molecule